Sirtex completes recruitment for SIRFLOX study
12 April, 2013 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has signed on the final patient for SIRFLOX, a trial of its SIR-Spheres liver cancer treatments that has been recruiting since 2006.
Patrys doses second group in myeloma trial
11 April, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has completed initial treatment for half of the 12 multiple myeloma patients to be involved in a clinical trial of anticancer antibody PAT-SM6.
Viralytics’ Cavatak well-tolerated intravenously
10 April, 2013 by Dylan Bushell-EmblingA phase I trial of intravenous delivery of Viralytics’ (ASX:VLA) Cavatak shows that the viral cancer treatment candidate was well tolerated.
Record funding for cancer research in the west
08 April, 2013The Cancer Council of Western Australia recently allocated $2.8 million in annual funding for research in Western Australia.
Applications open for cancer research funding
03 April, 2013The 2013 round of funding from the Australian Cancer Research Foundation is now open.
Philanthropy, advocacy and vision
03 April, 2013 by Susan WilliamsonResearch Australia has formed a collaborative international alliance with three advocacy groups.
Biolife breast cancer vaccine validated in journal
02 April, 2013The class of HER2/neu breast cancer vaccines to which Biolife Science’s HER-Vaxx belongs has been endorsed in a key breast cancer journal.
First Australian elected to Japanese Academy
27 March, 2013 by Susan WilliamsonProfessor Suzanne Cory is the first Australian to be admitted to the Japanese Academy of Science.
Cellmid close to royalties on cancer test licences
26 March, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) has provided an update on the two cancer diagnostics tests under development by its licensees using midkines as a biomarker.
Viralytics CEO hails cancer virotherapy milestone
22 March, 2013 by Dylan Bushell-EmblingViralytics (ASX:VLA) CEO Dr Malcolm McColl has called the news that Amgen met its goal with an oncolytic virus trial a “milestone event for the field.”
Prima to get $4.7m grant for cancer vaccine
21 March, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) will receive a $4.7m grant from Saxony Development Bank and will use the funds to explore the use of CVac in more cancer types beyond ovarian.
Patrys cancer antibody synergistic in myeloma
21 March, 2013 by Dylan Bushell-EmblingAnimal trials of Patrys’s (ASX:PAB) anticancer antibody PAT-SM6 suggest the treatment is more effective when combined with other multiple myeloma treatments.
New treatment effective for chronic pain
20 March, 2013A new device that stimulates the spinal cord provides relief for patients with difficult-to-treat chronic pain.
Biolife signs cancer vaccine manufacturing deal
19 March, 2013 by Dylan Bushell-EmblingBiolife Science has signed on Pevion Biotech to manufacture its HER-Vaxx anticancer vaccine in preparation for phase II trials in gastric cancer.
Emerging drug resistance in young malaria parasites
18 March, 2013 by Susan WilliamsonThe alarming rate at which the malaria parasite is developing resistance to drugs may be countered by changing the timing of the drug treatment and developing drugs that last longer in the bloodstream.
